• KOL
    • Atrial Fibrillation
    • Stefan Hans Hohnloser
    • Stefan Hans Hohnloser: Influence Statistics

      Stefan Hans Hohnloser

      Stefan Hans Hohnloser

      Show email address

      Department of Cardiology, J.W. Goethe University, 60590 Frankfurt, Germany;, hohnloser@em.uni-frankfurt.de | Center of Thrombosis and Hemostasis, University of Mainz, Mainz, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Stefan Hans Hohnloser:Expert Impact

      Concepts for whichStefan Hans Hohnloserhas direct influence:Atrial fibrillation,Patients atrial fibrillation,Myocardial infarction,Sinus rhythm,Catheter ablation,Heart failure,Cardiac death,Renal function.

      Stefan Hans Hohnloser:KOL impact

      Concepts related to the work of other authors for whichfor which Stefan Hans Hohnloser has influence:Atrial fibrillation,Heart failure,Catheter ablation,Oral anticoagulants,Myocardial infarction,Stroke prevention,Major bleeding.

      KOL Resume for Stefan Hans Hohnloser

      Year
      2022

      Department of Cardiology, J.W. Goethe University, 60590 Frankfurt, Germany;,

      Center of Thrombosis and Hemostasis, University of Mainz, Mainz, Germany

      2021

      Department of Cardiology, J. W. Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany.

      Dep. of Cardiology, J. W. Goethe University, Frankfurt, Germany

      2020

      JW Goethe University, Frankfurt, Germany.

      Duke Clinical Research Institute, 200 Morris St, Durham, NC 27701

      Department of Cardiology, Division of Clinical Electrophysiology, J. W. Goethe University, Frankfurt, Germany

      2019

      Division of Clinical Electrophysiology, Department of Cardiology, Johann Wolfgang Goethe University, Frankfurt, Germany.

      Department of Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

      Hamilton, Ontario

      2018

      Professor, Department of Molecular and Integrative Physiology

      Cyrus and Jane Farrehi Professor of Cardiovascular Research, Department of Internal Medicine

      Assistance Publique and Hôpitaux de Paris, Paris, France

      Senior Investigator, Fundación Centro Nacional de Investigaciones, Cardiovasculares (CNIC), Madrid, Spain

      Director, Cardiac Arrhythmia Program, Cardiovascular Division, Brigham and Women’s Hospital

      2017

      Klinikum der Stadt Ludwigshafen am Rhein, Medizinische Klinik B, Ludwigshafen (U.Z.), Boehringer Ingelheim, Ingelheim (S.G., M.N., E.K.), and Johann Wolfgang Goethe University, Department of Medicine, Division of Cardiology, Frankfurt am Main (S.H.H.) — all in Germany

      Klinik für Kardiologie, Abteilung für klinische Elektrophysiologie, J.-W. Goethe Universität Frankfurt, Frankfurt a. M., Deutschland

      2016

      Division of Clinical Electrophysiology, Department of Cardiology, J.W. Goethe University, Theodor-Stern-Kai 7, D 60590 Frankfurt am Main, Germany

      The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website

      2015

      Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

      Klinische Elektrophysiologie, Med. Klinik III, Kardiologie, J. W. Goethe Universität Frankfurt.

      2014

      J.W. Goethe University, Department of Cardiology, Frankfurt, Germany andDuke Clinical Research Institute, Duke Medicine, Durham, NC, USA

      J. W. Goethe University Department of Cardiology Frankfurt Germany

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Stefan Hans Hohnloser is among the top experts in the world.
      Concept World rank
      differences bleeding risk #1
      pore ic50 #1
      polypharmacy noac #1
      δipi #1
      atrial flutter comparison #1
      defibrillator interventions #1
      kcnq1 kcnq1wt #1
      reduction conventional pacing #1
      icd twa #1
      shocks symptomatic arrhythmias #1
      spectral method twa #1
      invasive testing recurrence #1
      benefit sinus rhythm #1
      safety intravenous tedisamil #1
      ventricular tachycardia year #1
      versus quinidine #1
      nonsustained hrv #1
      administered encainide #1
      nonsustained #1
      atrial therapy #1
      angiocardiography arrhythmias #1
      hrv autonomic modulation #1
      kcnq1 ikcnh2 #1
      q1 pore region #1
      spontaneous inducible #1
      postinfarction pacing #1
      ≥120 digitalis #1
      lvef testing #1
      pnn50 patients #1
      quinidine dispersion #1
      values 72 12 #1
      autonomic risk markers #1
      xvert trial #1
      24 median median #1
      hongatoxin #1
      surgical revision complications #1
      reproducibility hrv parameters #1
      superiority icd therapy #1
      negative coronary patients #1
      95 spontaneous inducible #1
      edoxaban vka #1
      encainide dosages #1
      implanted icds #1
      concept hybrid therapy #1
      ejection fraction benefit #1
      crt trials crt #1
      65 240 episodes #1
      azimilide hospitalizations #1
      apbs irat #1
      arrhythmias tests #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Stefan Hans Hohnloser

      KOL-Index: 19366

      BACKGROUND: In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of stroke but unsuitable for vitamin K antagonist therapy. We aimed to investigate whether the subgroup of patients with previous stroke or transient ischaemic attack (TIA) would show a greater benefit from apixaban compared with aspirin than would patients without previous cerebrovascular events.

      METHODS: In ...

      Known for Atrial Fibrillation | Patients Stroke | Apixaban Aspirin | Transient Ischaemic Attack | Systemic Embolism
      KOL-Index: 19245

      BACKGROUND: Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the ...

      Known for Cardiovascular Hospitalization | Dronedarone Patients | Stroke Atrial Fibrillation | Atrial Flutter | Antithrombotic Therapy
      KOL-Index: 19136

      BACKGROUND: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.

      METHODS AND RESULTS: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. ...

      Known for Warfarin Dabigatran | Atrial Fibrillation | Younger Patients | 2 Doses | Risk Major Bleeding
      KOL-Index: 18781

      BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding.

      METHODS: In this multicenter trial, we randomly assigned 2725 patients with atrial fibrillation who had undergone PCI to triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1 to 3 months) ...

      Known for Atrial Fibrillation | United States | Dual Therapy | Pci Risk | Hazard Ratio
      KOL-Index: 18539

      BACKGROUND: Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.

      METHODS: In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and ...

      Known for Atrial Fibrillation | Apixaban Patients | Year Aspirin | Hazard Ratio | Risk Stroke
      KOL-Index: 18409

      BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.

      METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with ...

      Known for Atrial Fibrillation | Year Apixaban | Warfarin Hazard Ratio | Rates Death | Stroke Patients
      KOL-Index: 18254

      AIMS: After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or elective PCI, and those receiving ticagrelor or clopidogrel treatment.

      METHODS AND RESULTS: In the RE-DUAL PCI trial, 2725 patients were randomized to dabigatran 110 mg or 150 mg with P2Y12 inhibitor, or warfarin with P2Y12 inhibitor and ...

      Known for Dual Therapy | Atrial Fibrillation | Coronary Intervention | Patients Acs | Elective Pci
      KOL-Index: 18211

      BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding.

      METHODS: ARISTOTLE was a double-blind, ...

      Known for Atrial Fibrillation | Apixaban Warfarin | Risk Stroke | Secondary Analysis | Systemic Embolism
      KOL-Index: 18205

      BACKGROUND: Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation.

      METHODS: A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were ...

      Known for Atrial Fibrillation | Clopidogrel Aspirin | Stroke Patients | Myocardial Infarction | Year Relative Risk
      KOL-Index: 17905

      BACKGROUND: Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation. This prespecified study investigated these ...

      Known for Renal Function | Atrial Fibrillation | Major Bleeding Patients | Systemic Embolism | Dabigatran Warfarin
      KOL-Index: 17786

      BACKGROUND: Thrombolysis has become the standard therapeutic approach in patients with acute myocardial infarction. To identify patients who may benefit from early invasive procedures, reliable noninvasive assessment of success or failure of thrombolytic therapy is mandatory.

      METHODS AND RESULTS: In a prospective study in 63 consecutive patients undergoing thrombolysis for their first myocardial infarction, serial measurements of creatine kinase (CK), its isoenzyme CK-MB, myoglobin, and ...

      Known for Creatine Kinase | Myoglobin Ck | Coronary Artery | 90 Minutes | Thrombolytic Therapy
      KOL-Index: 17506

      OBJECTIVES: This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.

      BACKGROUND: Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.

      METHODS: In the ARISTOTLE trial, ...

      Known for Aristotle Trial | Natriuretic Peptide | Apixaban Warfarin | Ntprobnp Levels | Stroke Mortality
      KOL-Index: 17334

      OBJECTIVES: The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in subjects treated with apixaban, an oral factor Xa inhibitor, compared with warfarin.

      BACKGROUND: In patients with atrial fibrillation, thromboembolic events may occur after cardioversion. This risk is lowered with vitamin K antagonists and dabigatran.

      METHODS: Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other ...

      Known for Atrial Fibrillation | Thromboembolic Events | Patients Cardioversion | Schedule Echocardiography | Receiving Warfarin
      KOL-Index: 17333

      IMPORTANCE: Renal impairment confers an increased risk of stroke, bleeding, and death in patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in relation to renal function changes over time.

      OBJECTIVES: To evaluate changes of renal function over time and their interactions with outcomes during a median of 1.8 years of follow-up in patients with atrial fibrillation randomized to apixaban vs warfarin treatment.

      DESIGN, SETTING, AND PARTICIPANTS: The ...

      Known for Renal Function | Patients Atrial Fibrillation | Apixaban Warfarin | Systemic Embolism | Major Bleeding
      KOL-Index: 17331

      IMPORTANCE: In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, weight 60 kg or less, and creatinine level 1.5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily. Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice daily dose of ...

      Known for Apixaban Patients | Low Body Weight | Advanced Age | Systemic Embolism | Major Bleeding

      Key People For Atrial Fibrillation

      Top KOLs in the world
      #1
      Gregory Yoke Hong Lip
      atrial fibrillation heart failure stroke prevention
      #2
      John Camm MD John Camm
      atrial fibrillation myocardial infarction heart rate
      #3
      Emelia J Benjamin
      atrial fibrillation framingham heart study heart failure
      #4
      Harry J G M C Crijns
      atrial fibrillation heart failure sinus rhythm
      #5
      Isabelle C Van Gelder
      atrial fibrillation heart failure rate control
      #6
      Stefan Hans Hohnloser
      atrial fibrillation myocardial infarction sinus rhythm

      Department of Cardiology, J.W. Goethe University, 60590 Frankfurt, Germany;, hohnloser@em.uni-frankfurt.de | Center of Thrombosis and Hemostasis, University of Mainz, Mainz, Germany | Department of Electrophysiology, J.W. Goetshe University, Frankfur

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.